Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony M Marchese

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Vaccines|July 27, 2024
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 VaccinesMatthew D Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
Vaccine|May 1, 2023
NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trialAnthony M Marchese, Xiang Zhou, John Kinol, et al.
Vaccines|January 22, 2024
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational StudyMatthew D Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
The Journal of Infection|October 17, 2024
Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccinesAnthony M Marchese, Louis Fries, Hadi Beyhaghi, et al.
Journal of Neurosurgery|November 26, 2021
Preoperative evaluation of coagulation status in neuromodulation patientsAmir Hadanny, Zachary T Olmsted, Anthony M Marchese, et al.
Human Vaccines & Immunotherapeutics|July 2, 2026
Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trialVivek Shinde, Wayne Woo, Anthony M Marchese, et al.
Scientific Reports|November 6, 2023
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variantsNita Patel, Jessica F Trost, Mimi Guebre-Xabier, et al.
Vaccine|February 16, 2024
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccineSeth Toback, Anthony M Marchese, Brandy Warren, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID VaccinesRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
The Journal of Infection|February 15, 2024
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccinesRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Vaccines|July 27, 2024
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 VaccinesMatthew D Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
Vaccine|May 1, 2023
NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trialAnthony M Marchese, Xiang Zhou, John Kinol, et al.
Vaccines|January 22, 2024
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational StudyMatthew D Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
The Journal of Infection|October 17, 2024
Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccinesAnthony M Marchese, Louis Fries, Hadi Beyhaghi, et al.
Journal of Neurosurgery|November 26, 2021
Preoperative evaluation of coagulation status in neuromodulation patientsAmir Hadanny, Zachary T Olmsted, Anthony M Marchese, et al.
Human Vaccines & Immunotherapeutics|July 2, 2026
Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trialVivek Shinde, Wayne Woo, Anthony M Marchese, et al.
Scientific Reports|November 6, 2023
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variantsNita Patel, Jessica F Trost, Mimi Guebre-Xabier, et al.
Vaccine|February 16, 2024
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccineSeth Toback, Anthony M Marchese, Brandy Warren, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID VaccinesRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
The Journal of Infection|February 15, 2024
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccinesRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Pageof 3